Navigation Links
University of Minnesota researchers discover enzyme behind breast cancer mutations
Date:2/6/2013

MINNEAPOLIS/SAINT PAUL (February 6, 2013) Researchers at the University of Minnesota have uncovered a human enzyme responsible for causing DNA mutations found in the majority of breast cancers. The discovery of this enzyme called APOBEC3B may change the way breast cancer is diagnosed and treated.

The findings from a team of researchers led by Reuben Harris, Ph.D., associate professor of biochemistry, molecular biology and biophysics and also a researcher at the Masonic Cancer Center, University of Minnesota, are published in the latest edition of Nature.

"We strongly believe this discovery will change the way mutations in cancer are viewed and, hopefully, it will allow cancer researchers to develop new treatments approaches that can prevent these mutations before they become harmful," said Harris.

Harris' quest to learn more about mutations in cancer initially began with HIV research. This previous work by Harris' lab and others indicated that APOBEC3B and related enzymes function normally to protect from infectious viruses like HIV-1.

During these studies, Harris' team developed specific tests to quantify the expression of each of the seven APOBEC3 genes, including APOBEC3B.

Harris and his team were able to apply these tests to the problem of mutation in breast cancer, showing only APOBEC3B is over-expressed in patients' breast cancer cell lines and tumors.

"DNA mutations are absolutely essential for cancer development," said Harris. "Our experiments showed the APOBEC3B enzyme causes mutations in the genome of breast cancer cells. From this, we were able to reasonably conclude that the APOBEC3B is a key influencer in breast cancer."

However, Harris points out that APOBEC3B appears to be a biological "double-edged sword." It protects some cells from viruses such as HIV-1 yet produces mutations giving rise to cancer in others.

Harris stresses the need for additional research. If further studies confirm that high APOBEC3B levels indicate the early presence of breast cancer, a simple blood test could be a strategy for early detection.

Another goal for Harris is finding a way to block APOBEC3B from causing mutation, just as sunscreen prevents sun from causing mutations leading to melanoma. His collaborative HIV studies are already pointing toward such drug possibilities.

"Our next steps will focus on the connections between high levels of APOBEC3B, age and other genetic risk factors that are known breast cancer markers. Ultimately, we hope our discovery leads to better therapeutic outcomes for patients," said Harris.


'/>"/>

Contact: Matt DePoint
mdepoint@umn.edu
612-625-4110
University of Minnesota Academic Health Center
Source:Eurekalert

Related medicine news :

1. University of California Irvine, Medical Center Selects Jvion as their ICD-10 Risk Assessment and Crosswalk Provider
2. Mainz University Medical Center receives further DFG funding for cardiovascular research
3. University of Tennessee researcher finds first time could predict sexual satisfaction
4. Lavender Languages Conference celebrates 20 years at American University
5. Spring Classes for Wexford University’s Online Doctoral Degree in Applied Sport Psychology Begin April 1
6. To Meet Growing Demand for Sports Psychology Experts, Wexford University Offers Master’s Degree in Applied Sport Psychology: Classes Begin April 1
7. Wexford University’s Master’s Degree in Nutrition and Exercises Prepares Weight Management Coaches and Consultants: Spring Quarter Launches April 1
8. Wayne State University researcher to evaluate success of text message diabetes intervention
9. University of Southern Mississippi Department of Marine Science Researches Marine Algae as Alternative Fuel Source
10. McGill University Launches a Major New Study on HPV Prevention Using Divine 9 Personal Lubricants with Carragel
11. Hospital of the University of Pennsylvania receives Comprehensive Stroke Center Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: